期刊文献+

液相色谱-串联质谱在生物样品定量测定中存在的不准确因素分析和对策 被引量:6

Discussions on the Inaccuracy Problems and Preventing Strategies Associated with the Use of Liquid Chromatography-Tandem Mass Spectrometry in Quantitative Assay of Biosamples
原文传递
导出
摘要 液相色谱-串联质谱(LC-MS/MS)技术是目前生物样本中小分子成分及部分蛋白和多肽定量分析中最广泛使用的技术。与LC相比,LC-MS/MS具有分析速度快、分辨率和灵敏度高、方法开发简单、可多组分同时测定等优点。在方法学开发过程中,分析者的主要操作一般是遵循法规的要求逐项进行方法学验证。但是,基于LC-MS/MS定量分析的原理,即使所建立的分析方法完全按照法规的要求进行了验证,在一些方面如不加以注意,也可能带来定量不准确的问题,即所谓的陷阱(生物分析风险)。笔者归纳了使用LC-MS/MS进行生物样本分析中常见的与不准确有关的问题,尤其是一些不能通过常规方法学验证发现的问题,包括:生物样本处理过程的逆转化、基质效应、源内裂解以及质荷比相近离子的干扰等。为了解决以上问题,除加强质量体系建设和进行严格的分析方法验证外,还可以采取去除基质效率高的样本处理方法、加强色谱分离、选择合适的离子反应、使用给药后样本进行方法学验证等措施。 Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is a widely used technique in the quantitative analysis of small molecules, part of peptides and proteins in biological matrix. When compared with LC, the LC-MS/MS posesses many advantages, such as high sample throughput, high sensitivity and resolutions, simple method development and simultaneous quantification of multiple components. At the stage of method development, the main practices for analysts are to validate analytical methods according to the regulated requirements. However, due to the quantitative mechanisms of LC-MS/MS, even though the used method is fully validated, analytical inaccuracy problem, which is the so called bioanalytical risk (pitfalls), may still exist, if we do not pay attentions to some details. In the present paper, the factors which may cause inaccuracy in quantitative analysis are summarized, especially those could not be found during routine method validation. Those factors include back transformation of unstable drug metabolites to analyte in the handling of biosamples, matrix effects, in-source conversion, and ion interference caused by ions with similar or same mass-to-charge ratio, etc. In addition to QA/QC oversight and strict method validation, the preventing strategies may contain the follows: selecting biosample processing method with high proficiency in eliminating matrix interferences, enhancing chromatographic separation, selection of suitable precursor-product ions and validation with incurred samples, etc.
出处 《中国药学杂志》 CAS CSCD 北大核心 2015年第11期925-930,共6页 Chinese Pharmaceutical Journal
关键词 液相色谱-串联质谱 生物样本 不准确性 生物分析风险 陷阱 基质效应 源内裂解 LC-MS/MS biosample inaccuracy bioanalytical risk pitfall matrix effect in-source conversion
  • 相关文献

参考文献29

  • 1JEMAL M. High throughput quantitative bioanalysis by LC-MS/ MS [J]. Biomed Chromatogr, 2000, 14(6) :422-429.
  • 2XU R N, FAN L, RIESER M J, et al. Recent advances in high- throughput quantitative bioanalysis by LC-klS/MS[ J]. J Pharm Biomed Anal,2007,44(2) :342-355.
  • 3KORFMARCHER W A. Principles and applications of LC-MS in new drug discovery [ J ]. Drug Discov Today, 2005, 10 ( 20 ) : 1357-1367.
  • 4CARTER G D. 25-Hydroxyvitamin D assays: The quest for accu- racy[J]. Clin Chem,2009 ,55 ( 7 ) :1300-1302.
  • 5SINGH R J. Are clinical laboratories prepared for accurate testing of 25-hydroxy vitamin D [ J ]. Clin Chem ,2008,54 ( 1 ) :221-223.
  • 6ZHOU M. Regulated Bioanalytical Laboratories: Technical and Regulatory Aspects from Global Perspectives [ M ]. New Jersey : Wi- ley, 2011 : 12-59 ;558-568.
  • 7魏敏吉,李可欣.符合法规和指南要求的生物样本分析[J].药物分析杂志,2014,34(1):12-16. 被引量:3
  • 8WEI M J, ZHANG Y H, ZHANG Z F. Accuracy problems during the analysis of biosamples and discussions on the improving meas- ures. [ DB/OL]. [2012-04-11 ]. http://www, cde. org. cn/dz- kw. do? method = largePage&id = 312642.
  • 9CFDA. Guideline on the Human Bioavailability and Bioequiva- lence of Chemical Drug Preparations(化学药物制剂人体生物利用度和生物等效性研究技术指导原则)[S].2005.
  • 10CFDA(国家食品药品管理局).Good Laboratory Practice for Nonclinical Laboratory Studies(药物非临床研究质量管理规范)[S].2003.

二级参考文献44

  • 1陈伟力,李雪宁,徐红蓉,储楠楠,周密.兰索拉唑及其代谢产物的生物等效性[J].中国临床药学杂志,2005,14(6):351-354. 被引量:10
  • 2FERLINI C, OJIMA I, DISTEFANO M, et al. Second generation taxanes: From the natural framework to the challenge of drug resistance[J]. Curr Med Chem Anti-Cancer Agents, 2003, 3: 133-138.
  • 3MIELE E, SPPINELLI G P, MIELE E, et al. Albumin-bound formulation of paclitaxel (Ahrax- ane ABI-007) in the treatment of breast cancer [J]. Int J Nanomedicine, 2009, (4): 99-105.
  • 4GARDERN E R, DAHUT W L, SCRIPTURE C D. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel [J]. Clin Cancer Res, 2008, 14(13): 4 199-4 205.
  • 5GRADISHAR W J. Albumin-bound paclitaxel: A next-generation taxane[J]. Expert Opin Pharma- cother, 2006, 7(8): 1 041-1 053.
  • 6JAMIS-DOW C A, KLECKER R W, KATKI AG, et al. Metabolism of taxol by human and rat liver in vitro., a screen for drug interactions and inter- species differences[J]. Cancer Chemother Pharma- col, 1995, 36: 107-114.
  • 7ANDERSON C D, WANG J, KUMAR G N, et al. Dexamethason induction of taxol metabolism in the rat[J]. Drug Metab Dispos, 1995, 23: 1 286-1 290.
  • 8MONSARRAT B, MARIEL E, Cros S, et al. T- axol metabolism isolation and identification of three major metabolites of taxol in rat bile [J]. Drug Metab Dispos, 1990, 18(6): 895-901.
  • 9ARORA V. Antisense strategies for redirection of drug metabolism:Using paclitaxel as a model[J]. Methods Mol Med, 2004, 106: 273-292.
  • 10SPRATLIN J, SAWYER M B. Pharmacogenetics of paclitaxel metabolism[J]. Crit Rev Oncol/He- matol, 2007, 61: 222-229.

共引文献6

同被引文献64

引证文献6

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部